Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Get Quote
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arcutis Biotherapeutics, Inc. - Common stock
(NQ:
ARQT
)
17.24
+0.09 (+0.52%)
Streaming Delayed Price
Updated: 3:09 PM EDT, Sep 8, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Arcutis Biotherapeutics, Inc. - Common stock
< Previous
1
2
3
4
5
Next >
Top 5 Biotech Stocks With Strong Momentum
August 28, 2025
Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.
Via
Benzinga
3 Biotech Catalysts Present Major Opportunity
August 25, 2025
Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further.
Via
MarketBeat
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Fits the Minervini Trend Template with Strong Growth Momentum
August 14, 2025
Discover how Arcutis Biotherapeutics (ARQT) fits Mark Minervini’s Trend Template with strong technicals, high growth momentum, and fast-improving earnings—ideal for growth investors.
Via
Chartmill
Arcutis (ARQT) Q2 Revenue Soars 164%
August 07, 2025
Via
The Motley Fool
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Beats Q2 2025 Revenue Estimates and Posts Narrower Loss Than Expected
August 06, 2025
Arcutis Biotherapeutics (ARQT) beats Q2 2025 revenue and EPS estimates with $81.5M in sales, driven by strong ZORYVE demand. Shares rise post-earnings.
Via
Chartmill
Earnings Scheduled For August 6, 2025
August 06, 2025
Via
Benzinga
Earnings Scheduled For May 6, 2025
May 06, 2025
Via
Benzinga
A Glimpse Into The Expert Outlook On Arcutis Biotherapeutics Through 5 Analysts
February 26, 2025
Via
Benzinga
Earnings Scheduled For February 25, 2025
February 25, 2025
Via
Benzinga
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
July 25, 2025
Via
Benzinga
Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis
June 06, 2025
Arcutis will present five posters at RAD 2025 featuring long-term safety and efficacy data for Zoryve cream in children with eczema.
Via
Benzinga
Analyst Expectations For Arcutis Biotherapeutics's Future
May 23, 2025
Via
Benzinga
Would Mark Minervini consider ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) a top stock pick?
April 24, 2025
A fundamental and technical analysis of (NASDAQ:ARQT): Is ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) suited for high growth investing?
Via
Chartmill
Demystifying Arcutis Biotherapeutics: Insights From 9 Analyst Reviews
April 03, 2025
Via
Benzinga
4 Analysts Have This To Say About Arcutis Biotherapeutics
February 10, 2025
Via
Benzinga
Demystifying Arcutis Biotherapeutics: Insights From 5 Analyst Reviews
January 13, 2025
Via
Benzinga
Assessing Arcutis Biotherapeutics: Insights From 4 Financial Analysts
August 28, 2024
Via
Benzinga
Rebound Or Fakeout? The 200-Day MA Holds The Key To The Next Big Move
March 25, 2025
A discussion whether the rebound could sustain, the worst scenario and the potential target price for the S&P 500.
Via
Talk Markets
Topics
Stocks
Stocks / Equities
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
March 25, 2025
Via
Benzinga
How does ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) stack up against Mark Minervini’s strategy?
March 25, 2025
A fundamental and technical analysis of (NASDAQ:ARQT): Why ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) is Poised for High Growth.
Via
Chartmill
Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?
March 23, 2025
Top performers last week: DGNX (108.29%), NEXT (25.07%), CELH (21.60%), SIG (21.08%), NFE (20.63%), MRP (16.61%), ARQT (16.35%), LCID (15.79%), CPRX (15.27%), STNE (14.20%). Are they in your...
Via
Benzinga
What's Going On With Arcutis Biotherapeutics Stock Monday?
March 17, 2025
Arcutis shares traded higher on Monday after Health Canada approved its Zoryve cream for the treatment of mild to moderate atopic dermatitis.
Via
Benzinga
Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally
February 26, 2025
Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.
Via
Stocktwits
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.
February 06, 2025
The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025.
Via
Investor's Business Daily
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
January 13, 2025
Via
Benzinga
This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
December 30, 2024
Via
Benzinga
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
December 30, 2024
Via
Benzinga
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
October 22, 2024
Via
Benzinga
CAVA Group Posts Strong Q2 Results, Joins Bilibili, Workday And Other Big Stocks Moving Higher On Friday
August 23, 2024
Via
Benzinga
Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session
August 15, 2024
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.